Advertisement

Time to Challenge Current Strategies for Detection of Barrett’s Esophagus and Esophageal Adenocarcinoma

  • David A. KatzkaEmail author
  • Rebecca C. Fitzgerald
CURRENT CLINICAL CONTROVERSY
  • 57 Downloads

Introduction

Adenocarcinoma of the esophagus (EAC) is a disease with a high mortality rate since initial detection usually occurs at an advanced stage in the majority of patients [1]. For example, data demonstrate that 50% of patients are diagnosed at stage II or higher with 20% diagnosed with stage IV disease [2]. As a result, even in this decade, the overall 5-year survival for EAC remains under 25% [2], despite increased efforts directed at increasing physician and patient awareness, multiple published society guidelines, and advances in endoscopic procedural quality and imaging. That the survival of EAC has not changed appreciably over the past two decades implies that a fundamental issue is not being addressed regarding the pathophysiology and classification of EAC. In this article, we will attempt to identify some of these issues.

De Novo Versus Surveillance-Detected EAC

It has long been recognized that that de novo EAC far outnumbers surveillance-detected EAC. A study...

Notes

Compliance with Ethical Standards

Conflict of interest

DAK was involved in Research funding Shire, Honorarium Celgene, and RCF was listed as an inventor on patents pertaining to Cytosponge and associated assays which have been licensed by the Medical Research Council to Medtronic.

References

  1. 1.
    Dubecz A, Gall I, Solymosi N, et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol. 2012;7:443–447.CrossRefGoogle Scholar
  2. 2.
    Tramontano AC, Sheehan DF, Yeh JM, et al. The impact of a prior diagnosis of Barrett’s esophagus on esophageal adenocarcinoma survival. Am J Gastroenterol. 2017;112:1256–1264.CrossRefGoogle Scholar
  3. 3.
    Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRefGoogle Scholar
  4. 4.
    Visrodia K, Singh S, Krishnamoorthi R, et al. Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2016;44:775–784.CrossRefGoogle Scholar
  5. 5.
    Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRefGoogle Scholar
  6. 6.
    Sawas T, Killcoyne S, Iyer PG, et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology. 2018;155:1720–1728. (e1724).CrossRefGoogle Scholar
  7. 7.
    Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg. 2009;138:594–602. (discussion 601-592).CrossRefGoogle Scholar
  8. 8.
    Hamade N, Vennelaganti S, Parasa S, et al. Lower annual rate of progression of short-segment vs long-segment Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2019;17:864–868.CrossRefGoogle Scholar
  9. 9.
    Visrodia K, Singh S, Krishnamoorthi R, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroenterology. 2015;150:599–607.CrossRefGoogle Scholar
  10. 10.
    Gaddam S, Singh M, Balasubramanian G, et al. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013;145:548–553. (e541).CrossRefGoogle Scholar
  11. 11.
    Krishnamoorthi R, Singh S, Ragunathan K, et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1046–1055. (e1048).CrossRefGoogle Scholar
  12. 12.
    Asge Standards of Practice C, Qumseya B, Sultan S, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359. (e332).CrossRefGoogle Scholar
  13. 13.
    Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76:531–538.CrossRefGoogle Scholar
  14. 14.
    Rubenstein JH, Thrift AP. Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:41–50.CrossRefGoogle Scholar
  15. 15.
    Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945–953. (e942).CrossRefGoogle Scholar
  16. 16.
    Honing J, Kievit W, Bookelaar J, Peters Y, Iyer PG, Siersema PD. Endosheath ultrathin transnasal endoscopy is a cost-effective method for screening for Barrett’s esophagus in patients with GERD symptoms. Gastrointest Endosc. 2018;89:712–722.CrossRefGoogle Scholar
  17. 17.
    Sami SS, Dunagan KT, Johnson ML, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110:148–158.CrossRefGoogle Scholar
  18. 18.
    Gora MJ, Sauk JS, Carruth RW, et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med. 2013;19:238–240.CrossRefGoogle Scholar
  19. 19.
    Mallick R, Patnaik SK, Wani S, Bansal A. A systematic review of esophageal MicroRNA markers for diagnosis and monitoring of Barrett’s esophagus. Dig Dis Sci. 2016;61:1039–1050.  https://doi.org/10.1007/s10620-015-3959-3.CrossRefPubMedGoogle Scholar
  20. 20.
    Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:2241–2255. (e2244).CrossRefGoogle Scholar
  21. 21.
    Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methylation panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. Gut. 2018;67:1942–1949.CrossRefGoogle Scholar
  22. 22.
    Elliott DRF, Walker AW, O’Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol. 2017;2:32–42.CrossRefGoogle Scholar
  23. 23.
    Januszewicz W, Tan WK, Lehovsky K, et al. Safety and acceptability of esophageal cytosponge cell collection device in a pooled analysis of data from individual patients. Clin Gastroenterol Hepatol.. 2019;17:647–656. (e641).CrossRefGoogle Scholar
  24. 24.
    Gharahkhani P, Fitzgerald RC, Vaughan TL, et al. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016;17:1363–1373.CrossRefGoogle Scholar
  25. 25.
    Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52. (quiz e13).CrossRefGoogle Scholar
  26. 26.
    Shaheen NJ, Falk GW, Iyer PG, Gerson LB, American College of G. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. (quiz 51).CrossRefGoogle Scholar
  27. 27.
    Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefGoogle Scholar
  28. 28.
    Sawas T, Manrique GC, Iyer PG, Wang KK, Katzka DA. Young adults with esophageal adenocarcinoma present with more advanced stage tumors and have shorter survival times. Clin Gastroenterol Hepatol. 2019;17:1756–1762.CrossRefGoogle Scholar
  29. 29.
    Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRefGoogle Scholar
  30. 30.
    Chen Q, Zhuang H, Liu Y. The association between obesity factor and esophageal caner. J Gastrointest Oncol. 2012;3:226–231.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomark Prev. 2008;17:352–358.CrossRefGoogle Scholar
  32. 32.
    Fang TC, Oh YS, Szabo A, Khan A, Dua KS. Utility of dysphagia grade in predicting endoscopic ultrasound T-stage of non-metastatic esophageal cancer. Dis Esophagus Off J Int Soc Dis Esophagus ISDE. 2015;29:642–648.CrossRefGoogle Scholar
  33. 33.
    Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology and Hepatology, Mayo 9Mayo ClinicRochesterUSA
  2. 2.Medical Research Council Cancer Unit, Hutchison/Medical Research Council Research CentreUniversity of CambridgeCambridgeUK

Personalised recommendations